Targeting N1-methyladenosine modification in osteoblasts through tRNA methyltransferase 10C reverses mitochondrial dysfunction and ameliorates osteoporosis [0.03%]
靶向成骨细胞中tRNA甲基转移酶10C的N1-甲基腺苷修饰逆转线粒体功能障碍并改善骨质疏松症
Haijian Sun,Wei Wang,Chi Zhang et al.
Haijian Sun et al.
Osteoporosis is among the most common degenerative systemic bone diseases and is accompanied by abnormally downregulated oxidative phosphorylation (OXPHOS) in osteoblasts. While mutations in the tRNA methyltransferase (TRMT10C) gene in huma...
Targeting intracellular cholesterol imbalance rescues sarcomere-ER contact site signaling and ER remodeling in dilated cardiomyopathy [0.03%]
靶向细胞内胆固醇不平衡可修复扩张型心肌病中的肌丝-内质网接点信号及内质网重塑问题
Nadezda Ignatyeva,Cleophas Cheruiyot,Hafiza Nosheen Saleem et al.
Nadezda Ignatyeva et al.
Dysregulated intracellular lipid metabolism emerged as a driver of heart failure (HF), a leading cause of death worldwide that is frequently caused by dilated cardiomyopathy (DCM). Yet, how defective lipid signaling destabilizes failing car...
Targeting oncogenic TβRI signaling inhibits androgen-independent prostate cancer growth and metastasis [0.03%]
靶向致癌TβRI信号抑制雄激素非依赖性前列腺癌生长和转移
Per Flodbring Larsson,Alexej Schmidt,Yabing Mu et al.
Per Flodbring Larsson et al.
Metastatic castration-resistant prostate cancer (mCRPC) remains the primary cause of prostate cancer-related mortality. Despite the availability of treatments, the molecular mechanisms underlying tumor invasion and metastasis are not fully ...
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial [0.03%]
新型新辅助疗法retlirafusp α（抗PD-L1/TGF-β双功能融合蛋白）联合或不联合化疗治疗不可切除的III期非小细胞肺癌：II期TRAILBLAZER试验的最新结果
Yi Pan,Xuening Yang,Qing Zhou et al.
Yi Pan et al.
TRAILBLAZER is a proof-of-concept phase 2 study (ClinicalTrials.gov, NCT04580498) of neoadjuvant retlirafusp alfa (an anti-PD-L1/TGF-β bifunctional agent) in unresectable stage III non-small cell lung cancer (NSCLC) not harboring EGFR or A...
Non-receptor tyrosine kinase signaling pathways and therapeutic implications [0.03%]
非受体酪氨酸激酶信号转导通路及其治疗意义
M D Anwar Hossain,Camila Marques Cuoco,Snigdha Hemant Sodaye et al.
M D Anwar Hossain et al.
Cell signaling regulates cellular physiological functions, including the cell cycle, survival, immune response, gene expression, and protein-protein interactions. Within this complex system and its intrinsic mechanisms, non-receptor tyrosin...
AKAP1 enhances glycogen accumulation and hepatocarcinogenesis through YTHDF2-mediated G6PC mRNA decay [0.03%]
通过YTHDF2介导的G6PCmRNA降解促进糖原累积和肝细胞癌变的AKAP1增强子
Tao Yang,Jiahao Zhang,Zifeng Zhao et al.
Tao Yang et al.
During recent years, a growing body of evidence has revealed that metabolic rewiring of glycogen is a hallmark of cancer that plays a significant role in tumor development and progression. Nonetheless, the molecular mechanism underlying the...
Multi-omics reveals microbiota, metabolite, and immunological heterogeneity of age-related endotypes in type 1 diabetes [0.03%]
多组学揭示1型糖尿病中与年龄相关的内表型的微生物组、代谢物和免疫异质性
Lanxin Pan,Huiling Tan,Tong Yue et al.
Lanxin Pan et al.
Type 1 diabetes (T1D) exhibits age-related heterogeneity in clinical progression and immune pathology, yet the underlying molecular mechanisms remain poorly understood. Here, we integrate microbiome, metabolome, lipidome, and transcriptome ...
Targeting the senescence‒autophagy axis via p16INK4a inhibition alleviates pulmonary fibrosis [0.03%]
通过抑制p16INK4a作用于衰老-自噬轴可缓解肺纤维化
Young Jo Yoo,Mi Zhang,Seung-Hyun Jin et al.
Young Jo Yoo et al.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease for which effective therapies are lacking. While cellular senescence and autophagy have been implicated in IPF pathogenesis, the intersecting mechanisms that drive ...
Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study [0.03%]
载多柔比星脂质体结合纳米白蛋白紫杉醇联合/不联合同期放化疗治疗腺样囊性癌患者：单臂Ⅱ期临床研究
Xinxin Zhang,Jian Wei,Nanxiang Chen et al.
Xinxin Zhang et al.
Given no standard therapies, this single-arm, open-label, multicenter phase II study was conducted in unresectable locally advanced or recurrent/metastatic adenoid cystic carcinoma of the head and neck (LA or R/M ACCHN). Patients received c...